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Hemophagocytic lymphohistiocytosis (HLH) is an unusual syndrome characterized by 
fever, hepatosplenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, 
and pathologic findings of hemophagocytosis in the bone marrow and other tissues. 
HLH may be familial or associated with different types of infections, autoimmune dis-
orders, or malignancies. Infection-associated HLH has been reported in various viral, 
bacterial, fungal, and parasitic infections, and case reports of parasitic infections im-
plicated in HLH include rare cases from Plasmodium vivax infection, which occasion-
ally affects both military personnel and civilians in Korea. We describe an unusual case 
of HLH resulting from Plasmodium vivax infection and review the literature. This case 
suggests that clinical suspicion of HLH is important when P. vivax infection is accom-
panied by cytopenias. Administration of antimalarial drugs may prevent irreversible 
end organ damage resulting from P. vivax-associated HLH.
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INTRODUCTION
　Hemophagocytic lymphohistiocytosis (HLH) is a rare 
syndrome characterized by reactive, systemic prolifera-
tion of benign histiocytes throughout the reticuloendo-
thelial system.
1 HLH results from impaired functions of 
natural killer (NK) and cytotoxic T cells, whereas activities 
of lymphocytes and histiocytes are augmented, leading to 
phagocytosis of hematopoietic cells.
1 HLH comprises two 
different conditions that may be difficult to distinguish 
from one another. The primary autosomal recessive form, 
familial hemophagocytic lymphohistiocytosis, is a fatal 
disease with its onset during infancy or early childhood and 
has a median survival of less than 2 months if untreated.
2 
Secondary HLH may develop as a result of strong immuno-
logical activation of the immune system, which may be 
caused by a severe infection. Among the infections, viral 
pathogens reported to be associated with HLH include 
Epstein-Barr virus, cytomegalovirus, parvovirus, herpes 
simplex virus, varicella-zoster virus, measles virus, hu-
man herpes virus-8, and human immunodeficiency virus, 
alone or in combination.
1 HLH may also coincide with vari-
ous bacterial infections, parasite infections, and fungal 
infections.
1 
　It is important to realize that early therapeutic inter-
ventions are required when strong clinical suspicion of in-
fection-associated HLH is present to prevent irreversible 
end organ damage. Our report describes an unusual case 
of HLH associated with Plasmodium vivax infection, which 
was treated successfully with antimalarial agents. We also 
review the literature on P. vivax-associated HLH. 
CASE REPORT
　A 64-year-old woman living in Gimpo, Gyeonggi 
Province, visited the emergency room of Seoul St. Mary’s 
Hospital, South Korea. She complained of chills followed 
by fever up to 40°C for several hours occurring every two 
days and diffuse abdominal pain for 7 days. She had not tak-
en any medication except that to treat reflux esophagitis. 
She had no history of traveling or contact with foreigners. 
Her vital signs were as follows: blood pressure 130/70 mm 
Hg, heart rate 96/min, temperature 38.2°C, and respira-
tory rate 24/min. She appeared acutely ill and hep-174
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FIG. 1. Peripheral blood smear of Plasmodium vivax-associated 
hemophagocytic lymphohistiocytosis. Double infection of a single
cell with trophozoite and mature macrogametocyte is noted. Also,
thrombocytopenia with mild normocytic normochromic anemia is
observed (Wright stain, ×1,000).
FIG. 2. Bone marrow aspirate from the patient with Plasmodium
vivax infection, showing phagocytosis by benign histiocytes. Addi-
tionally, slight megakaryocytic hyperplasia is noticed (Wright 
stain, ×400).
atosplenomegaly was noted, but there were no palpable 
lymph nodes. Her leukocyte count was 2,380/mm
3 (4,000- 
10,000/mm
3), her absolute neutrophil count was 830/mm
3, 
her hemoglobin was 11.7 g/dl (13.0-18.0 g/dl), her platelet 
count was 36,000/mm
3 (150,000-450,000/mm
3), and her re-
ticulocyte count was 0.52% (0.2-2%). Blood chemistry re-
vealed aspartate aminotransferase of 39 U/L (14-40 U/L), 
alanine aminotransferase of 30 U/L (9-45 U/L), total bilir-
ubin of 3.97 mg/dl (0.47-1.58 mg/dl), blood urea nitrogen of 
15.3 mg/dl (7.0-20.0 mg/dl), creatinine of 0.94 mg/dl (0.6-1.2 
mg/dl), lactate dehydrogenase of 1,451 U/L (250- 450 U/L), 
triglyceride of 210 mg/dl (40-200 mg/dl), and ferritin of 923 
μg/L (20-300 μg/L). The fibrinogen assay showed ＞500 
mg/dl (160-350 mg/dl). Cultures of blood and urine were 
done twice at 1-hour intervals, and all of the results were 
negative. Antibodies against viral pathogens including 
Epstein-Barr virus (EBV), cytomegalovirus (CMV), and 
herpes simplex virus (HSV) were not detected in the serum. 
Specifically, HSV IgM, HSV IgG, CMV IgM, EBV early an-
tigen IgG, and EBV viral capsid antigen (VCA) IgM were 
negative, but CMV IgG, EBV VCA IgG, and EBV nuclear 
antigen IgG were positive. Also, serologic tests for hepatitis 
A, B, and C viruses and human immunodeficiency virus 
were negative. Additional serologic tests for Leptospira, 
Orientia tsutsugamushi, Haantan virus, and connective 
tissue diseases were also negative, but trophozoites and ga-
metocytes of P. vivax were observed in a peripheral blood 
smear (Fig. 1), and the parasitemia value was 1,540/µL. 
Subsequent positive malaria polymerase chain reaction 
confirmed the diagnosis of P. vivax infection. A computed 
tomographic scan of the abdomen showed moderate he-
patosplenomegaly. Bone marrow aspirate revealed rare in-
tracellular parasites with hypocellular bone marrow, but 
proliferation of histiocytes with prominent hemophagocy-
tosis was noted (Fig. 2). Subsequent immunohistochemical 
stain for Epstein-Barr virus was negative. Diagnosis of P. 
vivax malaria-associated HLH was made, and hydroxy-
chloroquine (25 mg/kg) was administered for 3 days, fol-
lowed by primaquine (15 mg per day) for 14 days. The pa-
tient recovered completely with the antimalarial medi-
cation, and all the abnormal laboratory findings and fol-
low-up peripheral blood smear and bone marrow aspirate 
were normalized on the 12th day of hospitalization without 
additional implementation of immunosuppressive agents.
DISCUSSION
　The Histiocyte Society HLH study group revised the di-
agnostic guidelines of HLH in 2004.
3 According to them, the 
diagnosis of HLH is established either by a molecular diag-
nosis consistent with HLH (primary HLH) or by having five 
out of eight of the following: 1) fever; 2) splenomegaly; 3) 
cytopenia affecting more than two cell lineages; 4) hyper-
triglyceridemia and/or hypofibrinogenemia; 5) hemopha-
gocytosis in the bone marrow, spleen, or lymph nodes with-
out evidence of malignancy; 6) low or absent natural killer 
cell cytotoxicity; 7) hyperferritinemia; and 8) elevated solu-
ble CD25.
3 In our report, the patient presented with fever, 
hepatosplenomegaly, cytopenia of more than 2 cell line-
ages, hyperferritinemia, and hemophagocytosis in the 
bone marrow aspirates, meeting the diagnostic criteria for 
HLH (Table 1).
　Secondary HLH may occur most commonly in the setting 
of malignancy, autoimmune disease, drug hypersensi-
tivity reaction, or infection.
1 Infection-associated HLH has 
been reported in a great variety of viral, bacterial, fungal, 
and, rarely, parasitic infections.
1 P. vivax, a causative 
agent of relapsing tertian human malaria, is the second 
most important human malaria and affects several hun-
dred million people annually. It has the widest geographic 
distribution throughout the world, and is usually found in 
Central and South America, India, and Southeast Asia.
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TABLE 1. Diagnostic criteria for HLH 2004
3 
2004 diagnostic criteria for HLH Criteria fulfilled in index case
Clinical criteria
　Fever
　Splenomegaly
Laboratory criteria
　Cytopenia (affecting ≥2 of 3 cell lines in the peripheral blood)
　Hemoglobin ＜9 g/dl
　Platelet ＜100×10
3/dl 
　Neutrophil ＜1,000/dl
　Fibrinogen ＜1.5 g/L and/or 
　Hypertriglyceridemia (fasting triglyceride ≥3.0 mmol/l, i.e., ≥256 mg/dl) 
Histopathologic criteria
　Hemophagocytosis in bone marrow or spleen or lymph nodes
No evidence of malignancy
Additional criteria
　Low or absent NK cell activity
　Ferritin ＞500 μg/L
　Soluble CD 25 (i.e., IL 2 receptor) 2,400 U/ml
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
Not done
Yes
Not done
TABLE 2. Published cases of Plasmodium vivax-associated HLH
Age/Gender 41/F 23/M 22/M 64/F
Symptoms
Comorbidity
Hepatosplenomegaly
AST/ALT (U/L)
a
Total bilirubin (mg/dl)
The lowest:
  White blood cell (/mm
3)
  Hemoglobin (g/dl)
  Platelet (/mm
3)
Ferritin (μg/L)
Fibrinogen (mg/dl)
Triglyceride (mg/dl)
Bone marrow exam
Peripheral blood smear
  (stage of P. vivax) 
Treatment 
Outcome
Nation
Reference
Fever 
None
+
65/78
3.5
2,000
9.4
64,000
1,190
Normal
270
Hemophagocytic
  histiocytosis
Trophozoite and
  gametocyte 
Oral chloroquine
  and primaquine
Recovered
France
[4]
Fever 
None
+
546/391
3.41
2,590
15.4
53,000
＞1,000
-
-
Hemophagocytic
  histiocytosis
Trophozoite and
  gametocyte
Oral chloroquine
  and primaquine
Recovered
Korea
[5]
Fever
None
+
62/66
1.9
2,300
12.5
38,000
645.8
-
-
Hemophagocytic
  histiocytosis
Trophozoite and
  gametocyte
Oral chloroquine
  and primaquine
Recovered
Korea
[6]
Fever
None
+
39/30
3.97
2,380
11.7
36,000
923
＞500
210
Hemophagocytic
  histiocytosis
Trophozoite and
  gametocyte
Oral chloroquine
  and primaquine
Recovered
Korea
This case
aAST: aspartate aminotransferase, ALT: alanine aminotransferase.
Presently, P. vivax is the only endemic malarial species in 
Korea. 
　A search of the English and Korean language literature 
revealed seven other cases of P. vivax-associated HLH.
4-8 
Of these cases, patients’ data were available for four cases, 
including our case (Table 2).
4-6 In all four cases, including 
our case, treatment of P. vivax malaria was sufficient for 
the patients to recover, and no immunosuppressive agents 
were applied in any of these cases.
4-6
　The possible immunological mechanism of HLH may be 
excessive production of Th1 cytokines, such as interfer-
on-gamma, tumor necrosis factor-alpha, interleukin-1, or 
interleukin-6, from activated mononuclear cells.
9 Patients 
with Epstein-Barr virus-associated HLH, which can be fa-
tal due to hemorrhage, infection, or multi-organ failure, 
may be required to be treated with a combination of im-
munosuppressive agents.
10 Otherwise, patients with in-
fection-associated HLH with other pathogens can usually 
recover with supportive care and treatment targeted to the 
underlying infection.
10 Unless associated with underlying 176
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immunodeficiency, the outcome for HLH caused by para-
sitic infections, including P. vivax infection, is generally 
good when antimalarial drugs are properly applied, as oc-
curred in our patient.
4-6
　When a patient with bicytopenia or pancytopenia pres-
ents with fever or documented infection, the possibility of 
infection-associated HLH should be raised. In particular, 
systemic parasitic infections, such as malaria, should be in-
cluded in the differential diagnosis of pancytopenia and in-
fection-associated HLH. Laboratory tests to confirm the 
etiologic pathogen should be guided by epidemiological da-
ta and the patient’s medical history. In Korea, malaria from 
P. vivax infection has reemerged recently and shows a high 
transmission rate. When P. vivax -associated HLH is con-
firmed, administration of antimalarial drugs can result in 
the resolution of clinical symptoms and cytopenias without 
end organ damage. 
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